Tome Biosciences emerges with $213M funding for PASTE technology

Tome Biosciences, founded in 2021, emerged from stealth mode with $213 million in funding. Their PASTE technology, based on programmable genomic integration, allows precise DNA insertion. CEO Rahul Kakkar calls it the "final maturation of genomic sciences." The platform, combining CRISPR-Cas9 with proprietary integrases, can insert over 30kb of genetic code with unprecedented precision. Kakkar believes it will revolutionize gene and cell therapies, potentially treating rare monogenic diseases with a single drug.